OBJECTIVE: S-100B protein is a promising marker of injury severity and outcome after head injury. We examined the relationship between serum S-100B concentrations and injury severity, clinical course, survival, and treatment efficacy after severe traumatic brain injury (TBI). DESIGN AND SETTING: Prospective observational study in a neurosurgical intensive care unit. PATIENTS AND PARTICIPANTS: 102 adult patients with severe TBI, admitted between June 2001 and November 2003 (30 months). INTERVENTIONS: Serum S-100B levels were measured by immunoluminometric technique on admission and every 24 h thereafter for a maximum of 7 days. MEASUREMENTS AND RESULTS: Initial S-100B levels were significantly related to pupillary status, computed tomography severity 1, and 1-month survival. Cox's proportional hazard regression analysis showed that initial S-100B was an independent predictor of 1-month survival, in the presence of dilated pupils, and with increased age. Subjects with initial levels above 1 microg/l had a nearly threefold increased probability of death within 1 month. Serum S-100B alteration indicated neurological improvement or deterioration. Finally, surgical treatment reduced S-100B levels. CONCLUSIONS: Serum S-100B protein reflects injury severity and improves prediction of outcome after severe TBI. S-100B may also have a role in assessing the efficacy of treatment after severe TBI.
OBJECTIVE:S-100B protein is a promising marker of injury severity and outcome after head injury. We examined the relationship between serum S-100B concentrations and injury severity, clinical course, survival, and treatment efficacy after severe traumatic brain injury (TBI). DESIGN AND SETTING: Prospective observational study in a neurosurgical intensive care unit. PATIENTS AND PARTICIPANTS: 102 adult patients with severe TBI, admitted between June 2001 and November 2003 (30 months). INTERVENTIONS: Serum S-100B levels were measured by immunoluminometric technique on admission and every 24 h thereafter for a maximum of 7 days. MEASUREMENTS AND RESULTS: Initial S-100B levels were significantly related to pupillary status, computed tomography severity 1, and 1-month survival. Cox's proportional hazard regression analysis showed that initial S-100B was an independent predictor of 1-month survival, in the presence of dilated pupils, and with increased age. Subjects with initial levels above 1 microg/l had a nearly threefold increased probability of death within 1 month. Serum S-100B alteration indicated neurological improvement or deterioration. Finally, surgical treatment reduced S-100B levels. CONCLUSIONS: Serum S-100B protein reflects injury severity and improves prediction of outcome after severe TBI. S-100B may also have a role in assessing the efficacy of treatment after severe TBI.
Authors: Linda Papa; Lawrence M Lewis; Jay L Falk; Zhiqun Zhang; Salvatore Silvestri; Philip Giordano; Gretchen M Brophy; Jason A Demery; Neha K Dixit; Ian Ferguson; Ming Cheng Liu; Jixiang Mo; Linnet Akinyi; Kara Schmid; Stefania Mondello; Claudia S Robertson; Frank C Tortella; Ronald L Hayes; Kevin K W Wang Journal: Ann Emerg Med Date: 2011-11-08 Impact factor: 5.721
Authors: Richard Rubenstein; Binggong Chang; Peter Davies; Amy K Wagner; Claudia S Robertson; Kevin K W Wang Journal: J Neurotrauma Date: 2014-12-23 Impact factor: 5.269
Authors: Keisuke Kawata; Charles Y Liu; Steven F Merkel; Servio H Ramirez; Ryan T Tierney; Dianne Langford Journal: Neurosci Biobehav Rev Date: 2016-05-12 Impact factor: 8.989
Authors: Linda Papa; Claudia S Robertson; Kevin K W Wang; Gretchen M Brophy; H Julia Hannay; Shelley Heaton; Ilona Schmalfuss; Andrea Gabrielli; Ronald L Hayes; Steven A Robicsek Journal: Neurocrit Care Date: 2015-02 Impact factor: 3.210